Seres Therapeutics, Inc. - MCRB STOCK NEWS

Seres Therapeutics (NASDAQ: MCRB) announced that CEO Eric Shaff will participate in a panel at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 10:30 a.m. ET. An audio webcast of the discussion will be available on their website, with a replay accessible for 21 days post-event.

Seres is recognized for its pioneering work in microbiome therapeutics, highlighted by its SER-109 program, which has achieved positive clinical results for treating C. difficile infections. Additionally, SER-301 and SER-155 are in Phase 1b studies targeting ulcerative colitis and infection prevention in medically compromised patients.

Seres Therapeutics (MCRB) announced its fourth quarter and full year 2021 financial results, reporting a net loss of $65.6 million for the year, improving from a loss of $89.1 million in 2020. Significant progress was noted in the Phase 3 ECOSPOR III study of SER-109 for recurrent C. difficile infection (rCDI), achieving its primary endpoint. A Biologics License Application (BLA) filing is anticipated in mid-2022, potentially making SER-109 the first microbiome therapeutic approved. The company also launched SER-155 for Infection Protection and reported cash reserves of approximately $291.2 million.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on March 1, 2022, at 8:30 a.m. ET to discuss its Q4 2021 and full-year results, along with a general business update. Investors can join by calling 844-277-9450 for domestic or 336-525-7139 for international access, referencing conference ID 6277858. The event will also be available for live streaming on their website. Seres' SER-109 program achieved positive clinical results and has received FDA Breakthrough Therapy and Orphan Drug designations, targeting recurrent C. difficile infection.

Seres Therapeutics (Nasdaq: MCRB) announced that CEO Eric Shaff will present at the Chardan Metagenomics and Microbiome Medicines Summit on March 1, 2022, at 2:00 p.m. ET. An audio webcast of the presentation will be available on the company's website, with a replay accessible one hour post-event for 21 days. Seres is a pioneer in microbiome therapeutics, with its SER-109 program showing promising results for treating C. difficile infections. The company is also conducting Phase 1b studies for SER-301 and SER-155 targeting ulcerative colitis and infection prevention, respectively.

Seres Therapeutics, Inc. (Nasdaq: MCRB) announced the appointment of Paula Cloghessy as Executive Vice President and Chief People Officer effective February 7, 2022. Her extensive 20+ years in HR within biotechnology and pharmaceuticals aims to enhance the company’s culture and support its growth, particularly in advancing SER-109 towards FDA approval. Cloghessy emphasizes talent development and employee engagement, ensuring a positive work environment. This strategic hiring comes as Seres continues its pioneering efforts in microbiome therapeutics.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a webcast investor event on January 31, 2022, from 8:30 a.m. to 10:00 a.m. ET, focusing on microbiome therapeutics for infection protection. Clinical data from the Phase 3 ECOSPOR III trial showed that SER-109 significantly reduced CDI recurrence, with 88% of patients achieving a sustained clinical response. Additionally, SER-155 is being evaluated in patients at risk of serious infections. The event will feature discussions on new infection prevention strategies and the role of microbiome therapeutics.

Seres Therapeutics (MCRB) announced significant results from its Phase 3 ECOSPOR III study on SER-109, an oral microbiome therapeutic for recurrent C. difficile infection. The study demonstrated an 88% sustained clinical response in patients taking SER-109, compared to 60% with placebo. Furthermore, SER-109 was well tolerated, mirroring placebo safety profiles. The company plans to finalize its Biologics License Application (BLA) filing by mid-2022, aiming for FDA approval. These findings published in the New England Journal of Medicine highlight SER-109's potential to transform treatment standards for rCDI.

Seres Therapeutics, Inc. (Nasdaq: MCRB) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 8:15 a.m. ET. A live audio webcast will be available on the company's website, with a replay accessible one hour post-event for 21 days. Seres focuses on microbiome therapeutics, showcasing its SER-109 program, which received Breakthrough Therapy and Orphan Drug designations from the FDA for treating recurrent C. difficile infections. Additionally, SER-301 and SER-155 are under evaluation in clinical studies for ulcerative colitis and gastrointestinal infections.

Seres Therapeutics (NASDAQ: MCRB) reported preliminary findings from the Phase 2b ECO-RESET study of SER-287 for treating ulcerative colitis, revealing successful engraftment of bacterial species. Despite the primary endpoints not being met, engraftment results were statistically significant (p ≤ 0.001). The company is exploring potential biomarker-based patient selection for future trials. Ongoing analysis of SER-287 and SER-301 data is expected to guide further development steps in ulcerative colitis.